Uterine leiomyomas are benign tumors that originate from the myometrium. Evidence points
to ovarian steroid hormones, in particular, progesterone as major promoters of leiomyoma …

BACKGROUND: There are concerns that intrauterine device (IUD) use by women with
uterine fibroids might increase their uterine bleeding or risk for device expulsion. The …

OBJECTIVE: To examine the association between premenopausal use of the levonorgestrel-
releasing intrauterine system and cancer incidence in Finland with a special focus on …

Background Many risk factors in uterine fibroid development have been identified, but
women and their physicians are less aware of the influence of lifestyle on uterine fibroid …

A systematic review is done to determine the efficacy and safety of levonorgestrel-releasing
intrauterine systems as a treatment using in premenopausal women with symptomatic …

Objective: To evaluate the efficacy of the levonorgestrel-releasing intrauterine system (LNG-
IUS) in the treatment of leiomyoma related menorrhagia and to assess the effect of LNG-IUS …

Levonorgestrel-(LNG) releasing intrauterine device (IUD) insertion revealed significant
reduction in visual bleeding scores and spotting with an increase in amenorrhea and uterine …

Family planning represents a key component of reproductive health care. Accordingly, the
provision of contraception must span the reproductive age spectrum, including …

Uterine leiomyomas are benign, estrogen-sensitive, fibrotic smooth muscle cell tumors
occurring in the uterine myometrium. Leiomyomas are a considerable health burden, with a …

Intrauterine progestins, progesterone receptor modulators, and antagonists have many
important current and potential gynecologic applications. This article will describe the …